Related Industry Reports:
- World Neurodegenerative Diseases Market 2009-2024
- The World Alzheimer's Disease Market (Incidence, Treatments, Key Companies, Pipeline and Trends)
- UpdatesPlus Nicotinic Receptors - Current Research and Development - February 2009
- UpdatesPlus-Nicotinic Receptors (February 2008)
- Pipeline Report - Neuronal alpha 7 nicotinic receptors: Candidates for the treatment of Alzheimers disease and Schizophrenia
In vitro ADMET and physicochemical investigations of poly-N-methylated peptides designed to inhibit Abeta aggregation.
Bioorganic & medicinal chemistry 2010 Jul 1; In press
Bose P PP, Chatterjee U, Hubatsch I, Artursson P, Govender T, Kruger H HG, Bergh M, Johansson J, Arvidsson P PI
Department of Biochemistry & Organic Chemistry, Uppsala University, Box 576, SE-751 23 Uppsala, Sweden.
N-Methylation is a common strategy for improving oral bioavailability of peptide-based lead structures. Herein, we present a detailed study on how the degree of N-methylation affects the absorption-distribution-metabolism-excretion-toxicity (ADMET) properties such as solubility, membrane transport, proteolytic stability, and general cell toxicity of the investigated peptides. As representative structures we chose hexapeptides 1-8. These peptides, corresponding to N-methylated analogues of residues 16-21 and 32-37 of the Abeta-peptide, pathological hallmark of Alzheimer's disease (AD), have previously been shown to inhibit aggregation of Abeta fibrils in vitro. This study suggests that poly-N-methylated peptides are non-toxic and have enhanced proteolytic stability over their non-methylated analogues. Furthermore, solubility in aqueous solution is seen to increase with increased degree of N-methylation, while membrane transport was found to be low for all investigated hexapeptides. The present results, together with those reported in the literature, suggest that poly-N-methylated peptides, especially shorter or equal to six residues, can be suitable candidates for drug design.